This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Complete. BGI and Beta Acquisition Corporation filed a tender offer statement with the SEC on September 25, 2012, and mailed an offer to purchase, forms of letter of transmittal and related documents to Complete's stockholders. Complete filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC on September 25, 2012, and mailed the Schedule 14D-9 to Complete's stockholders. These documents, as they may be amended from time to time, contain important information about the Offer, and stockholders of Complete are urged to read them carefully.Investors may obtain a free copy of these documents and other relevant documents filed with the SEC through the website maintained by the SEC at www.sec.gov. In addition, investors and stockholders will be able to obtain free copies of these materials filed by Complete by contacting Investor Relations by telephone at (650) 943-2788, by mail at Complete Genomics, Inc., Investor Relations, 2071 Stierlin Court, Mountain View, California 94043, or by going to Complete's Investor Relations page on its corporate website at www.completegenomics.com.
For BGI-Shenzhen:In the U.S.:Jason GolzBrunswick GroupTel: (415) 671-7676 email@example.com In China: Elizabeth LiangBrunswick GroupTel: +852 3512-5000 firstname.lastname@example.orgSOURCE BGI-Shenzhen